Sign in or create an account to add this stock to your watchlist.
About Paratek Pharmaceuticals (NASDAQ:PRTK)
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PRTK
CUSIP89354M10
Phone617-807-6600
Debt
Debt-to-Equity Ratio0.47
Current Ratio8.06
Quick Ratio8.06
Price-To-Earnings
Trailing P/E Ratio-3.18
Forward P/E Ratio-2.93
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.62 million
Price / Sales26.29
Cash FlowN/A
Price / CashN/A
Book Value$3.51 per share
Price / Book2.99
Profitability
EPS (Most Recent Fiscal Year)($3.30)
Net Income$-89,060,000.00
Net Margins-707.08%
Return on Equity-87.29%
Return on Assets-50.20%
Miscellaneous
Employees83
Outstanding Shares31,600,000
Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions
What is Paratek Pharmaceuticals' stock symbol?
Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."
How were Paratek Pharmaceuticals' earnings last quarter?
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) released its earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.94) by $0.03. The specialty pharmaceutical company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.02 million. Paratek Pharmaceuticals had a negative return on equity of 87.29% and a negative net margin of 707.08%. View Paratek Pharmaceuticals' Earnings History.
What price target have analysts set for PRTK?
7 brokerages have issued 12-month price objectives for Paratek Pharmaceuticals' stock. Their forecasts range from $36.00 to $55.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $45.00 in the next year. View Analyst Ratings for Paratek Pharmaceuticals.
Are investors shorting Paratek Pharmaceuticals?
Paratek Pharmaceuticals saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 4,049,664 shares, an increase of 61.9% from the April 13th total of 2,500,701 shares. Based on an average trading volume of 1,122,559 shares, the days-to-cover ratio is presently 3.6 days. Currently, 15.7% of the company's stock are sold short.
Who are some of Paratek Pharmaceuticals' key competitors?
Some companies that are related to Paratek Pharmaceuticals include Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Impax Laboratories (IPXL), Endo International (ENDP), TherapeuticsMD (TXMD), Immuron (IMRN), Mallinckrodt (MNK), Radius Health (RDUS), Myovant Sciences (MYOV), Theravance Biopharma (TBPH), Biohaven Pharmaceutical (BHVN), WAVE Life Sciences (WVE), Amneal Pharmaceuticals (AMRX), Intra-Cellular Therapies (ITCI) and Apellis Pharmaceuticals (APLS).
Who are Paratek Pharmaceuticals' key executives?
Paratek Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Bigham, Chairman & CEO (Age 60)
- Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 59)
- Mr. Douglas W. Pagán, Chief Financial Officer (Age 46)
- Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. Adam Woodrow, Chief Commercial Officer and VP (Age 51)
Has Paratek Pharmaceuticals been receiving favorable news coverage?
Media coverage about PRTK stock has been trending somewhat negative this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of -0.01 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 47.16 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Paratek Pharmaceuticals' major shareholders?
Paratek Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.42%), Highland Capital Management LP (3.04%), C WorldWide Group Holding A S (1.58%), Northern Trust Corp (1.14%), Water Island Capital LLC (0.81%) and JPMorgan Chase & Co. (0.72%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Fund Iv LP Omega, Michael Bigham and Robert S Radie. View Institutional Ownership Trends for Paratek Pharmaceuticals.
Which major investors are selling Paratek Pharmaceuticals stock?
PRTK stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, C WorldWide Group Holding A S, Prosight Management LP, JPMorgan Chase & Co. and Opus Point Partners Management LLC. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham and Robert S Radie. View Insider Buying and Selling for Paratek Pharmaceuticals.
Which major investors are buying Paratek Pharmaceuticals stock?
PRTK stock was acquired by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Omni Partners LLP, BlackRock Inc., California Public Employees Retirement System, Water Island Capital LLC, A.R.T. Advisors LLC, Trellus Management Company LLC and Northern Trust Corp. Company insiders that have bought Paratek Pharmaceuticals stock in the last two years include Fund Iv LP Omega and Michael Bigham. View Insider Buying and Selling for Paratek Pharmaceuticals.
How do I buy shares of Paratek Pharmaceuticals?
Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Paratek Pharmaceuticals' stock price today?
One share of PRTK stock can currently be purchased for approximately $10.50.
How big of a company is Paratek Pharmaceuticals?
Paratek Pharmaceuticals has a market capitalization of $350.72 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.
How can I contact Paratek Pharmaceuticals?
Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]
MarketBeat Community Rating for Paratek Pharmaceuticals (PRTK)
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
Paratek Pharmaceuticals (NASDAQ:PRTK) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Paratek Pharmaceuticals in the last 12 months. Their average twelve-month price target is $45.00, suggesting that the stock has a possible upside of 328.57%. The high price target for PRTK is $55.00 and the low price target for PRTK is $36.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.14 | 3.14 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $45.00 | $45.00 | $42.7143 | $42.7143 |
| Price Target Upside: | 328.57% upside | 242.21% upside | 128.42% upside | 91.12% upside |
Paratek Pharmaceuticals (NASDAQ:PRTK) Consensus Price Target History
Paratek Pharmaceuticals (NASDAQ:PRTK) Analyst Ratings History
Show:
(Data available from 5/23/2016 forward)
Paratek Pharmaceuticals (NASDAQ:PRTK) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/14/2014 | special | $1.33 | | 6/4/2014 | 5/26/2014 | 6/3/2014 |
(Data available from 1/1/2013 forward)
Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 77.40%
Paratek Pharmaceuticals (NASDAQ PRTK) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Adam Woodrow | VP | Sell | 5,700 | $12.70 | $72,390.00 | 89,167 |  |
| 4/9/2018 | Douglas W Pagan | CFO | Sell | 5,237 | $12.70 | $66,509.90 | 77,083 | |
| 4/9/2018 | Evan Loh | COO | Sell | 8,084 | $12.70 | $102,666.80 | 214,786 | |
| 4/9/2018 | Michael Bigham | Chairman | Sell | 8,700 | $12.70 | $110,490.00 | 199,730 | |
| 2/6/2018 | Adam Woodrow | VP | Sell | 14,333 | $13.87 | $198,798.71 | 62,367 | |
| 2/5/2018 | Douglas W Pagan | CFO | Sell | 16,291 | $14.22 | $231,658.02 | 39,570 | |
| 2/5/2018 | Evan Loh | COO | Sell | 3,040 | $14.22 | $43,228.80 | 144,870 | |
| 2/5/2018 | Michael Bigham | Chairman | Sell | 4,000 | $14.22 | $56,880.00 | 123,680 | |
| 2/5/2018 | Robert S Radie | Director | Sell | 3,000 | $14.22 | $42,660.00 | 9,330 | |
| 7/5/2017 | Adam Woodrow | VP | Sell | 3,800 | $23.58 | $89,604.00 | 69,500 | |
| 7/5/2017 | Douglas W Pagan | CFO | Sell | 4,139 | $23.58 | $97,597.62 | 60,000 | |
| 7/5/2017 | Evan Loh | COO | Sell | 4,351 | $23.58 | $102,596.58 | 112,783 | |
| 7/5/2017 | Michael Bigham | Chairman | Sell | 5,075 | $23.58 | $119,668.50 | 109,500 | |
| 6/19/2017 | Douglas W Pagan | CFO | Sell | 4,595 | $25.00 | $114,875.00 | 51,000 | |
| 2/6/2017 | Douglas W Pagan | CFO | Sell | 3,405 | $15.09 | $51,381.45 | 58,983 | |
| 2/6/2017 | Evan Loh | COO | Sell | 3,106 | $15.09 | $46,869.54 | 102,873 | |
| 2/6/2017 | Michael Bigham | Chairman | Sell | 5,000 | $15.09 | $75,450.00 | 99,970 | |
| 6/27/2016 | Fund Iv L.P. Omega | Major Shareholder | Buy | 461,538 | $13.00 | $5,999,994.00 | | |
| 6/23/2016 | Michael Bigham | CEO | Buy | 20,000 | $13.45 | $269,000.00 | 100,000 | |
| 12/11/2015 | Evan Loh | CMO | Buy | 2,300 | $16.87 | $38,801.00 | 80,389 | |
| 5/29/2015 | Hbm Healthcare Investments (Ca | Major Shareholder | Sell | 20,580 | $30.75 | $632,835.00 | | |
| 12/13/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 1,470 | $3.54 | $5,203.80 | | |
| 12/11/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 10,490 | $3.55 | $37,239.50 | | |
| 12/6/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 8,710 | $3.54 | $30,833.40 | | |
| 12/4/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 7,120 | $3.50 | $24,920.00 | | |
| 11/20/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 10,040 | $3.57 | $35,842.80 | | |
| 11/12/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 7,190 | $3.53 | $25,380.70 | | |
| 11/7/2013 | Roumell Asset Management, Llc | major shareholder | Sell | 4,960 | $3.61 | $17,905.60 | | |
| 10/30/2013 | Roumell Asset Management, Llc | Major Shareholder | Sell | 7,020 | $3.69 | $25,903.80 | | |
(Data available from 1/1/2013 forward)
Paratek Pharmaceuticals (NASDAQ PRTK) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity
finance.yahoo.com - May 22 at 4:34 PM |
| What Investors Should Know About Paratek Pharmaceuticals Inc’s (NASDAQ:PRTK) Financial Strength
finance.yahoo.com - May 21 at 4:36 PM |
 | Equities Analysts Issue Forecasts for Paratek Pharmaceuticals, Inc.'s Q2 2018 Earnings (PRTK)
www.americanbankingnews.com - May 21 at 1:04 AM |
| Gabelli Research Analysts Decrease Earnings Estimates for Paratek Pharmaceuticals, Inc. (PRTK)
www.americanbankingnews.com - May 14 at 5:11 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) to Post Q2 2018 Earnings of ($0.94) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - May 14 at 1:56 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 13 at 3:33 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 12 at 1:06 AM |
| Paratek Pharmaceuticals (PRTK) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 10 at 4:46 PM |
| Edited Transcript of PRTK earnings conference call or presentation 9-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 9:27 AM |
| Paratek Pharmaceuticals (PRTK) PT Set at $50.00 by Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 6:23 PM |
 | Paratek Pharmaceuticals' (PRTK) CEO Michael Bigham on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 4:43 PM |
| Paratek up 1% on Q1 result
seekingalpha.com - May 9 at 9:17 AM |
| 5 Biotech Stocks Set to Beat Estimates This Earnings Season
finance.yahoo.com - May 9 at 9:17 AM |
| Paratek: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:17 AM |
| Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:17 AM |
| Is Paratek Pharmaceuticals Oversold?
seekingalpha.com - May 3 at 9:06 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Short Interest Update
www.americanbankingnews.com - April 29 at 3:12 AM |
| Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
finance.yahoo.com - April 26 at 9:03 AM |
 | Paratek Pharmaceuticals Presents Data Supporting Potential Approval of Omadacycline for Treatment of Community ...
globenewswire.com - April 25 at 4:47 PM |
| Paratek Pharmaceuticals (PRTK) to Release Earnings on Wednesday
www.americanbankingnews.com - April 25 at 6:32 AM |
| Paratek Pharmaceuticals (PRTK) Downgraded by BidaskClub to Strong Sell
www.americanbankingnews.com - April 24 at 9:58 AM |
| Paratek's omadacycline on par with moxifloxacin in late-stage study in CABP
seekingalpha.com - April 23 at 4:36 PM |
 | Paratek Pharmaceuticals (PRTK) Prices $140 Million of Convertible Senior Subordinated Notes due 2024
www.streetinsider.com - April 20 at 9:23 AM |
 | Here's Why Paratek Pharmaceuticals Dropped as Much as 16.6% Today
www.msn.com - April 19 at 4:49 PM |
| Here's Why Paratek Pharmaceuticals Dropped as Much as 16.6% Today
finance.yahoo.com - April 19 at 4:49 PM |
| Paratek Pharmaceuticals (PRTK) Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024
www.streetinsider.com - April 19 at 9:11 AM |
| Paratek Pharmaceuticals, Inc. Prices $140 Million of Convertible Senior Subordinated Notes due 2024
finance.yahoo.com - April 19 at 9:11 AM |
| Paratek Pharma launches $125M convertible debt offering
seekingalpha.com - April 18 at 4:54 PM |
| Paratek Pharmaceuticals, Inc. Announces Proposed Private Offering of $125 Million of Convertible Senior Subordinated Notes due 2024
finance.yahoo.com - April 18 at 4:54 PM |
| Brokers Set Expectations for Paratek Pharmaceuticals, Inc.'s Q1 2018 Earnings (PRTK)
www.americanbankingnews.com - April 18 at 7:52 AM |
| Paratek Pharmaceuticals, Inc. (PRTK) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 18 at 3:21 AM |
| Paratek Pharmaceuticals (PRTK) Price Target Raised to $43.00
www.americanbankingnews.com - April 17 at 7:34 PM |
| Analysts Offer Predictions for Paratek Pharmaceuticals, Inc.'s FY2020 Earnings (PRTK)
www.americanbankingnews.com - April 17 at 7:05 AM |
| BidaskClub Downgrades Paratek Pharmaceuticals (PRTK) to Buy
www.americanbankingnews.com - April 16 at 5:24 PM |
 | Technical Perspectives on Biotech Stocks -- Pain Therapeutics, Paratek Pharma, PDL BioPharma, and Progenics ...
www.prnewswire.com - April 16 at 9:07 AM |
 | BRIEF-Paratek Appoints Rolf Hoffman To Co's Board Of Directors
www.reuters.com - April 14 at 4:25 PM |
| Paratek Pharmaceuticals (PRTK) Names Rolf K. Hoffman to Board
www.streetinsider.com - April 14 at 4:25 PM |
| Paratek Pharmaceuticals (PRTK) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - April 14 at 10:43 AM |
| Paratek Appoints Rolf K. Hoffman to Company’s Board of Directors
finance.yahoo.com - April 14 at 9:22 AM |
| Paratek Pharmaceuticals Presenting New Data from Omadacycline Development Program at ECCMID 2018
finance.yahoo.com - April 12 at 10:03 AM |
| Evan Loh Sells 8,084 Shares of Paratek Pharmaceuticals Inc (PRTK) Stock
www.americanbankingnews.com - April 10 at 10:16 PM |
| Paratek Pharmaceuticals Inc (PRTK) Chairman Michael Bigham Sells 8,700 Shares
www.americanbankingnews.com - April 10 at 10:16 PM |
| Insider Selling: Paratek Pharmaceuticals Inc (PRTK) VP Sells 5,700 Shares of Stock
www.americanbankingnews.com - April 10 at 10:16 PM |
| Douglas W. Pagan Sells 5,237 Shares of Paratek Pharmaceuticals Inc (PRTK) Stock
www.americanbankingnews.com - April 10 at 10:16 PM |
| Paratek Pharmaceuticals (PRTK) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - April 10 at 8:55 PM |
| Paratek Pharmaceuticals (PRTK) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 4:40 PM |
| Paratek Pharmaceuticals (PRTK) Now Covered by Analysts at Guggenheim
www.americanbankingnews.com - April 5 at 8:30 PM |
| Paratek's (PRTK) NDA for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
www.streetinsider.com - April 5 at 4:37 PM |
| Paratek's (PRTK) NDAs for Omadacycline Get Priority Review
www.msn.com - April 5 at 4:37 PM |
| Paratek's (PRTK) NDAs for Omadacycline Get Priority Review
finance.yahoo.com - April 5 at 4:37 PM |
Paratek Pharmaceuticals (NASDAQ:PRTK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Paratek Pharmaceuticals (NASDAQ:PRTK) Income Statement, Balance Sheet and Cash Flow Statement
Paratek Pharmaceuticals (NASDAQ PRTK) Stock Chart for Wednesday, May, 23, 2018
Loading chart…
